Evidence map›Paper›PMID 29686296›Full record

ArticleScientific reports2018

A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model.

Parth N Shah, Kush N Shah, Justin A Smolen, Jasur A Tagaev, Jose Torrealba, Lan Zhou, Shiyi Zhang, Fuwu Zhang, Patrick O Wagers, Matthew J Panzner and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Pyoverdine-Dependent Virulence ofFrontiers in microbiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Parth N ShahDepartment of Microbial Pathogenesis and Immunology, Texas A & M Health Science Center, College Station, TX, 77843, United States.
Kush N ShahDepartment of Microbial Pathogenesis and Immunology, Texas A & M Health Science Center, College Station, TX, 77843, United States.
Justin A SmolenDepartment of Chemistry, Department of Chemical Engineering, Department of Materials Science and Engineering, and Laboratory for Synthetic-Biologic Interactions, Texas A & M University, College Station, TX, 77842, United States.
Jasur A TagaevTashkent Paediatric Medical Institute, Tashkent, 100140, Uzbekistan.
Jose TorrealbaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, United States.
Lan ZhouDepartment of Statistics, Texas A & M University, College Station, TX, 77842, United States.
Shiyi ZhangDepartment of Chemistry, Department of Chemical Engineering, Department of Materials Science and Engineering, and Laboratory for Synthetic-Biologic Interactions, Texas A & M University, College Station, TX, 77842, United States.
Fuwu ZhangDepartment of Chemistry, Department of Chemical Engineering, Department of Materials Science and Engineering, and Laboratory for Synthetic-Biologic Interactions, Texas A & M University, College Station, TX, 77842, United States.
Patrick O WagersDepartment of Chemistry and Center for Silver Therapeutics Research, The University of Akron, Akron, OH, 44325, United States.
Matthew J PanznerDepartment of Chemistry and Center for Silver Therapeutics Research, The University of Akron, Akron, OH, 44325, United States.
Wiley J YoungsDepartment of Chemistry and Center for Silver Therapeutics Research, The University of Akron, Akron, OH, 44325, United States.
Karen L WooleyDepartment of Chemistry, Department of Chemical Engineering, Department of Materials Science and Engineering, and Laboratory for Synthetic-Biologic Interactions, Texas A & M University, College Station, TX, 77842, United States.
Carolyn L CannonDepartment of Microbial Pathogenesis and Immunology, Texas A & M Health Science Center, College Station, TX, 77843, United States. cannon@medicine.tamhsc.edu.
Texas A&M University · USTexas A&M Health Science Center · USUniversity of Akron · USTashkent Pediatric Medical Institute · UZThe University of Texas Southwestern Medical Center · US

Funding

NHLBI NIH HHS HHSN268201000046C
6 · The paper itself

Abstract

To address the escalating problem of antimicrobial resistance and the dwindling antimicrobial pipeline, we have developed a library of novel aerosolizable silver-based antimicrobials, particularly for the treatment of pulmonary infections. To rapidly screen this library and identify promising candidates, we have devised a novel in vitro metric, named the "drug efficacy metric" (DEM), which integrates both the antibacterial activity and the on-target, host cell cytotoxicity. DEMs calculated using an on-target human bronchial epithelial cell-line correlates well (R

Indexed as

AnimalsAnti-Bacterial AgentsBronchiCells, CulturedDisease Models, AnimalHumansIn Vitro TechniquesMaleMetal NanoparticlesMiceMice, Inbred C57BLPneumoniaPseudomonas aeruginosaPseudomonas InfectionsSilverAnti-Bacterial AgentsSilver

Identifiers

PMID29686296
PMCPMC5913254
OpenAlexW2807494281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.